MHRA recalls batches of betahistine dihydrochloride tablets

The Medicines and Healthcare products Regulatory Agency has issued a recall for batches of betahistine dihydrochloride 8mg and 16mg tablets.

The regulator advised healthcare professionals to stop supplying certain batches immediately, quarantine all stock and return it to their supplier after what it described as “a cross-contamination issue:.

“Kent Pharmaceuticals Ltd has informed us that several batches of finished product were contaminated with theophylline due to a cross-contamination issue identified with an excipient that was used in the manufacture of the finished product,” the MHRA said.

The affected 8mg batches of are EC10619, EC10719, EC10819 while the 16mg batches are GY11119, GY11219 and GY11319.

“The risk of adverse reactions is low with respect to the level of contamination. However, if patients experience any side effects related to hypersensitivity or those not normally experienced with betahistine, please ensure appropriate clinical advice is sought from your healthcare team. Any suspected side effects should also be reported via the Yellow Card scheme,” the MHRA said.

Latest discussions

  1. Pre reg exams

    Thanks for your comments both - Richard ...

  2. Pre reg exams

    Having been qualified just over 40 years...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.